title: [Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)].
abstract: The efficacy and safety of bi-weekly administration of medium-dose docetaxel (TXT) were evaluated in patients with advanced and recurrent breast cancers. The additional effect of 5'-DFUR for non-responders was also evaluated. Forty patients with advanced and recurrent breast cancers were treated and 38 cases of 40 were evaluated (34 with recurrent cases and 4 with advanced cases). All cases were female, and their mean age was 56.0 (38-74). TXT of 60 mg/body, which was equivalent to 30-50 mg/m2 for standard-sized Japanese women, was administered every two weeks. 5'-DFUR of 800 mg/body was added for non-responders after 5 weeks. The response rate was calculated from the data of 32 cases with measurable lesions, and side effects were evaluated in about 34 cases with exact records. Two hundred seventy-one courses were performed for 38 patients (4-24 courses per person, average 7.13 courses). The mean dosage per course of TXT was 58.4 mg/body (38.3 mg/ m2). Three complete and 7 partial responses were observed (overall response rate: 31.3%). Ten non-responders were evaluated for the additional effect of 5' DFUR, and one case reached PR. Grade 3/4 bone marrow suppression occurred in 9 patients, and Grade 3/4 general malaise was observed in two patient. According to the results, bi-weekly administration of medium dose TXT is an active and safe regimen in patients with advanced and recurrent breast cancers. The additional effect of 5'-DFUR was observed in one of 10 non-responders of bi-weekly chemotherapy with medium-dose TXT.
authors.affiliation: Dept of Surgery, Shiga Medical School.
authors.forename: Shozo
authors.initials: S
authors.lastname: Fujino
authors.forename: Norimichi
authors.initials: N
authors.lastname: Kan
authors.forename: Chol Joo
authors.initials: CJ
authors.lastname: Lee
authors.forename: Takashi
authors.initials: T
authors.lastname: Inamoto
authors.forename: Keiichi
authors.initials: K
authors.lastname: Mise
authors.forename: Seiji
authors.initials: S
authors.lastname: Sawai
authors.forename: Masahiko
authors.initials: M
authors.lastname: Okamoto
authors.forename: Satoru
authors.initials: S
authors.lastname: Nishimura
authors.forename: Taisuke
authors.initials: T
authors.lastname: Hori
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Maruhashi
authors.forename: Akira
authors.initials: A
authors.lastname: Yamauchi
authors.forename: Koji
authors.initials: K
authors.lastname: Fujii
authors.forename: Michihide
authors.initials: M
authors.lastname: Mitsumori
authors.forename: Shunichi
authors.initials: S
authors.lastname: Higashide
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Takemoto
authors.forename: Takahito
authors.initials: T
authors.lastname: Okamura
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D005467:Floxuridine; D000077143:Docetaxel; C025034:doxifluridine